Skip to main content

Windtree Therapeutics, Inc. (WINT)

NASDAQ: WINT · IEX Real-Time Price · USD
2.28 0.00 (0.00%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap60.89M
Revenue (ttm)n/a
Net Income (ttm)-62.82M
Shares Out26.35M
EPS (ttm)-3.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume188,479
Open2.28
Previous Close2.28
Day's Range2.26 - 2.30
52-Week Range1.58 - 7.53
Beta-0.07
AnalystsStrong Buy
Price Target10.50 (+360.5%)
Est. Earnings DateNov 4, 2021

About WINT

Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in pr...

IndustryBiotechnology
IPO DateAug 8, 1995
Employees31
Stock ExchangeNASDAQ
Ticker SymbolWINT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for WINT stock is "Strong Buy" and the 12-month stock price forecast is 10.50.

Price Target
$10.50
(360.53% upside)
Analyst Consensus: Strong Buy

News

Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming D...

Tuesday, October 19th @ 8:00 am Eastern Time Tuesday, October 19th @ 8:00 am Eastern Time

3 days ago - GlobeNewsWire

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Trea...

Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 Billion

5 days ago - GlobeNewsWire

Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for ac...

1 month ago - GlobeNewsWire

Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acu...

2 months ago - GlobeNewsWire

Windtree to Present at Access to Giving Virtual Investor Conference

WARRINGTON, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acu...

3 months ago - GlobeNewsWire

Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)

WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acu...

3 months ago - GlobeNewsWire

Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel

WARRINGTON, Pa., July 1, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ca...

3 months ago - PRNewsWire

Meme Penny Stocks, What Are They, and 3 to Watch Right Now

Meme penny stocks are in focus right now, what are they, and which small-caps are investors watching? The post Meme Penny Stocks, What Are They, and 3 to Watch Right Now appeared first on Penny Stocks t...

Other symbols:BBIGFTFT
4 months ago - PennyStocks

Why Windtree Therapeutics Stock Is Moving Today

Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 pric...

4 months ago - Benzinga

Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., May 13, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ca...

5 months ago - PRNewsWire

Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent

WARRINGTON, Pa., April 19, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...

5 months ago - PRNewsWire

7 Beaten Down Stocks with Significant Insider Buying

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

6 months ago - InvestorPlace

2 Falling Knives to Catch

Wall Street recommends buying shares of NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) and Windtree Therapeutics Inc (NASDAQ:WINT), even though these two securities have shown poor performance over the prior...

Other symbols:NRBO
6 months ago - GuruFocus

Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., March 29, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute ...

6 months ago - PRNewsWire

Windtree Therapeutics Announces Closing of $30.0 Million Public Offering

WARRINGTON, Pa., March 25, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...

6 months ago - PRNewsWire

Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering

WARRINGTON, Pa., March 23, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...

6 months ago - PRNewsWire

Windtree Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

WARRINGTON, Pa., March 22, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-...

6 months ago - PRNewsWire

Windtree Therapeutics' AEROSURF Drug Delivery Device Secures US Patent

United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,874,818 to Windtree Therapeutics Inc (NASDAQ: WINT), covering features of the aerosol delivery system for AEROSURF drug de...

8 months ago - Benzinga

Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 16, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute c...

11 months ago - PRNewsWire

Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical devi...

1 year ago - GlobeNewsWire

Why Windtree Therapeutics Shares Are Trading Higher Today

Windtree Therapeutics Inc (NASDAQ: WINT) shares are trading higher on Wednesday. The company announced the initial European trial sites activated for its AEROSURF Bridging study and a collaboration for ...

1 year ago - Benzinga